Identification of factors affecting the success of next-generation sequencing testing in solid tumors

American Journal of Clinical Pathology

Volumn 145, Issue 2, 2016, Pages 222-237

  Goswami, Rashmi S ^a,b   Luthra, Rajyalakshmi ^a   Singh, Rajesh R ^a   Patel, Keyur P ^a   Routbort, Mark J ^a   Aldape, Kenneth D ^a,b   Yao, Hui ^a   Dang, Hyvan D ^a   Barkoh, Bedia A ^a   Manekia, Jawad ^a   Medeiros, L Jeffrey ^a   Roy Chowdhuri, Sinchita ^a   Stewart, John ^a   Broaddus, Russell R ^a   Chen, Hui ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Ion Torrent; Next generation sequencing; Preanalytical tissue factors; Targeted hotspot mutation; Tissue qualification

Indexed keywords

DNA; FORMIC ACID; PARAFFIN; TUMOR MARKER;

ARTICLE; BIOPSY TECHNIQUE; CONTROLLED STUDY; CYTOLOGY; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN TISSUE; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR; TUMOR VOLUME; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MUTATION; NEOPLASMS; SPECIMEN HANDLING; TISSUE FIXATION; WORKFLOW;

BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING; TISSUE FIXATION; WORKFLOW;

EID: 84959449694     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1093/AJCP/AQV023     Document Type: Article

References (27)

1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931-945.
2. McPherson JD, Marra M, Hillier L, et al. A physical map of the human genome. Nature. 2001;409:934-941.
3. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304-1351.
4. Koboldt DC, Steinberg KM, Larson DE, et al. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155:27-38.
5. Siroy AE, Boland GM, Milton DR, et al. Beyond BRAF: clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015;135:508-515.
6. Paniz-Mondolfi A, Singh R, Jour G, et al. Cutaneous carci-nosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch. 2014;465:339-350.
7. Portier BP, Kanagal-Shamanna R, Luthra R, et al. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014;141:559-572.
8. Moreira AL, Won HH, McMillan R, et al. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. J Thorac Oncol. 2015;10:373-380.
9. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015;121:448-456.
10. Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med. 2014;20:1027-1034.
11. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998-2006.
12. Varghese AM, Zakowski MF, Yu HA, et al. Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol. 2014;9:892-896.
13. Cheng DT, Cheng J, Mitchell TN, et al. Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data. J Mol Diagn. 2014;16:504-518.
14. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
15. Routbort MJ, Handal B, Patel KP, et al. OncoSeek: a versatile annotation and reporting system for next generation sequencing-based clinical mutation analysis of cancer specimens. J Mol Diagn. 2012;14:747.
16. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev. 2011;32:177-195.
17. Weiss MM, Van der Zwaag B, Jongbloed JD, et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum Mutat. 2013;34:1313-1321.
18. Dubbink HJ, Deans ZC, Tops BB, et al. Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol. 2014;8:830-839.
19. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15:733-747.
20. Gargis AS, Kalman L, Berry MW, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012;30:1033-1036.
21. Luthra R, Patel KP, Reddy NG, et al. Next generation sequencing based multi-gene mutational screen foracute mye-loid leukemia using miseq: applicability for diagnostics and disease monitoring. Haematologica. 2014;99:465-473.
22. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hot-spots in 46 cancer-related genes. J Mol Diagn. 2013;15:607-622.
23. Kanagal-Shamanna R, Portier BP, Singh RR, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014;27:314-327.
24. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399-405.
25. Barrett MT, Lenkiewicz E, Evers L, et al. Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol. 2013;4:2.
26. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14:178-192.
27. Singh VM, Salunga RC, Huang VJ, et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol. 2013;17:322-326.